HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Background HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti‐epidermal growth factor receptor (EGFR) treatment...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2019-10, Vol.24 (10), p.1395-1402
Hauptverfasser:	Sartore‐Bianchi, Andrea, Amatu, Alessio, Porcu, Luca, Ghezzi, Silvia, Lonardi, Sara, Leone, Francesco, Bergamo, Francesca, Fenocchio, Elisabetta, Martinelli, Erika, Borelli, Beatrice, Tosi, Federica, Racca, Patrizia, Valtorta, Emanuele, Bonoldi, Emanuela, Martino, Cosimo, Vaghi, Caterina, Marrapese, Giovanna, Ciardiello, Fortunato, Zagonel, Vittorina, Bardelli, Alberto, Trusolino, Livio, Torri, Valter, Marsoni, Silvia, Siena, Salvatore
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti‐EGFR monoclonal antibodies Colorectal cancer ERBB2 Gastrointestinal Cancer HER2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!